BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncolo... ( WOBURN Mass. May 15 /- BioVex Inc a...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

Date:5/15/2009

WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29, 2009 - June 2, 2009 in Orlando, FL.

The results are to be presented in an abstract (number 6018) entitled, "Phase I/II dose escalation study of OncoVEX GM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)," at a poster session on Friday, May 29, 2009 from 2:00pm - 6:00pm EDT on Level 2, West Hall F3 of the conference. A poster discussion will take place from 5:00pm - 6:00pm EDT.

Study Rationale

Patients with head and neck cancer often present with bulky disease that is too large or too close to vital organs for surgical removal. These patients typically undergo radiation and chemotherapy treatment prior to surgery. Patients who present with tumor containing lymph nodes are particularly difficult to treat and approximately half of these patients relapse within two years.

In this study, OncoVEX GM-CSF was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 Stage III/IVA (N1-3) patients treated, 16 had N2 or N3 disease.

Study Results

The abstract, now available online at www.asco.org, reports that OncoVEX GM-CSF was well tolerated, with no significant additional side effects noted over and above those which are common with chemoradiation alone.
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs

Post Your Comments:

[0] Helix BioPharma Corp. Announces Fiscal Q1 2010 Results [0] Reportlinker Adds Medical Fiber Optics - A World Market Analysis [0] Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide

Other Medicine Technology:Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 2 Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 3 Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2 Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3 Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4 Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5 Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6

Cambridge Laboratories Announces Approval of Tetrabenazine in Spain Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

Breaking Medicine News(10 mins):Health News:Genetic Test May Someday Help Spot Breast Cancer 2 Health News:Genetic Test May Someday Help Spot Breast Cancer 3 Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2 Health News:Video Contest With $5,000 CASH Prize!!! 2 Health News:Hoag Hospital Named One of the Nation's Top Cardiovascular Hospitals by Thomson Reuters 2 Health News:Hoag Hospital Named One of the Nation's Top Cardiovascular Hospitals by Thomson Reuters 3 Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 2 Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 3

[0] Genetic Test May Someday Help Spot Breast Cancer [0] Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award [1] Video Contest With $5,000 CASH Prize!!![0] Hoag Hospital Named One of the Nation's Top Cardiovascular Hospitals by Thomson Reuters [0] Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn

Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial Electronic Prescribing Saves Patients Money 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research American Lung Association of Minnesota: Get a Flu Shot This Week -- It's National Vaccination Week The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza Houston Mother Who Nearly Lost Her Daughter to Influenza Joins American Lung Association's Faces of Influenza Campaign to Promote Annual Vaccination

Medicine Products:

AlAliMed® Footdrop Night Splint™QualCare™ Compression Ankle Support Pediatric Ankle Cryo/Cuff™VenaFlow® System

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncolo...( WOBURN Mass. May 15 /- BioVex Inc a...),Health